Literature DB >> 12532467

Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases.

Li-Qun Yang1, Shen-Jing Li, Yun-Fei Cao, Xiao-Bo Man, Wei-Feng Yu, Hong-Yang Wang, Meng-Chao Wu.   

Abstract

AIM: To determine whether parenchymal cells or hepatic cytochrome P450 protein was changed in chronic liver diseases, and to compare the difference of CYP3A4 enzyme and its gene expression between patients with hepatic cirrhosis and obstructive jaundice, and to investigate the pharmacologic significance behind this difference.
METHODS: Liver samples were obtained from patients undergoing hepatic surgery with hepatic cirrhosis (n=6) and obstructive jaundice (n=6) and hepatic angeioma (controls, n=6). CYP3A4 activity and protein were determined by Nash and western blotting using specific polychonal antibody, respectively. Total hepatic RNA was extracted and CYP3A4cDNA probe was prepared according the method of random primer marking, and difference of cyp3a4 expression was compared among those patients by Northern blotting.
RESULTS: Compared to control group, the CYP3A4 activity and protein in liver tissue among patients with cirrhosis were evidently reduced. (P<0.01) Northern blot showed the same change in its mRNA levels. In contrast, the isoenzyme and its gene expression were not changed among patients with obstructive jaundice.
CONCLUSION: Hepatic levels of P450s and its CYP3A4 isoform activity were selectively changed in different chronic liver diseases. CYP3A4 isoenzyme and its activity declined among patients with hepatic cirrhosis as expression of cyp3a4 gene was significantly reduced. Liver's ability to eliminate many clinical therapeutic drug substrates would decline consequently. These findings may have practical implications for the use of drugs in patients with cirrhosis and emphasize the need to understand the metabolic fate of therapeutic compounds. Elucidation of the reasons for these different changes in hepatic CYP3A4 may provide insight into more fundamental aspects and mechanisms of imparied liver function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12532467      PMCID: PMC4611347          DOI: 10.3748/wjg.v9.i2.359

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  51 in total

1.  Effects of epidermal growth factor on CYP inducibility by xenobiotics, DNA replication, and caspase activations in collagen I gel sandwich cultures of rat hepatocytes.

Authors:  K De Smet; P Loyer; D Gilot; A Vercruysse; V Rogiers; C Guguen-Guillouzo
Journal:  Biochem Pharmacol       Date:  2001-05-15       Impact factor: 5.858

Review 2.  Mechanisms of hepatotoxicity.

Authors:  Hartmut Jaeschke; Gregory J Gores; Arthur I Cederbaum; Jack A Hinson; Dominique Pessayre; John J Lemasters
Journal:  Toxicol Sci       Date:  2002-02       Impact factor: 4.849

Review 3.  Cyp3A regulation: from pharmacology to nuclear receptors.

Authors:  L C Quattrochi; P S Guzelian
Journal:  Drug Metab Dispos       Date:  2001-05       Impact factor: 3.922

Review 4.  Gender-related differences in pharmacokinetics and their clinical significance.

Authors:  E Tanaka
Journal:  J Clin Pharm Ther       Date:  1999-10       Impact factor: 2.512

5.  Independent patterns of cytochrome P450 gene expression in liver and blood in patients with suspected liver disease.

Authors:  N Finnström; M Thörn; L Lööf; A Rane
Journal:  Eur J Clin Pharmacol       Date:  2001-08       Impact factor: 2.953

6.  Fentanyl inhibits metabolism of midazolam: competitive inhibition of CYP3A4 in vitro.

Authors:  Y Oda; K Mizutani; I Hase; T Nakamoto; N Hamaoka; A Asada
Journal:  Br J Anaesth       Date:  1999-06       Impact factor: 9.166

Review 7.  Ethanol metabolism, cirrhosis and alcoholism.

Authors:  C S Lieber
Journal:  Clin Chim Acta       Date:  1997-01-03       Impact factor: 3.786

8.  Interaction of methadone with substrates of human hepatic cytochrome P450 3A4.

Authors:  C Iribarne; Y Dréano; L G Bardou; J F Ménez; F Berthou
Journal:  Toxicology       Date:  1997-02-14       Impact factor: 4.221

9.  Cytochrome P450 2E1 genetic polymorphism and gastric cancer in Changle, Fujian Province.

Authors:  L Cai; S Z Yu; Z F Zhan
Journal:  World J Gastroenterol       Date:  2001-12       Impact factor: 5.742

10.  Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.

Authors:  Yvonne S Lin; Amy L S Dowling; Sean D Quigley; Federico M Farin; Jiong Zhang; Jatinder Lamba; Erin G Schuetz; Kenneth E Thummel
Journal:  Mol Pharmacol       Date:  2002-07       Impact factor: 4.436

View more
  27 in total

Review 1.  Implications of opioid analgesia for medically complicated patients.

Authors:  Howard Smith; Patricia Bruckenthal
Journal:  Drugs Aging       Date:  2010-05       Impact factor: 3.923

Review 2.  Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications.

Authors:  Cindy J Bednasz; Charles S Venuto; Qing Ma; Gene D Morse
Journal:  Clin Pharmacol Drug Dev       Date:  2017-03

3.  A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.

Authors:  Trevor N Johnson; Koen Boussery; Karen Rowland-Yeo; Geoffrey T Tucker; Amin Rostami-Hodjegan
Journal:  Clin Pharmacokinet       Date:  2010-03       Impact factor: 6.447

Review 4.  Drug development and use in the elderly: search for the right dose and dosing regimen (Parts I and II).

Authors:  Rashmi R Shah
Journal:  Br J Clin Pharmacol       Date:  2004-11       Impact factor: 4.335

Review 5.  Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.

Authors:  Alexander Elkader; Beth Sproule
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 6.  Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.

Authors:  Gail D Anderson; Shahin Hakimian
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

Review 7.  Dose adjustment in patients with liver disease.

Authors:  Fabiola Delcò; Lydia Tchambaz; Raymond Schlienger; Jürgen Drewe; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 8.  Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.

Authors:  Mark K Greenwald; Sandra D Comer; David A Fiellin
Journal:  Drug Alcohol Depend       Date:  2014-08-19       Impact factor: 4.492

9.  Pharmacokinetics of oltipraz in diabetic rats with liver cirrhosis.

Authors:  C Y Ahn; S K Bae; S H Bae; T Kim; Y S Jung; Y C Kim; M G Lee; W G Shin
Journal:  Br J Pharmacol       Date:  2009-03       Impact factor: 8.739

10.  Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis.

Authors:  Craig D Fisher; Jonathan P Jackson; Andrew J Lickteig; Lisa M Augustine; Nathan J Cherrington
Journal:  Arch Toxicol       Date:  2008-05-17       Impact factor: 5.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.